[HTML][HTML] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC …
JY Lee, X Qing, W Xiumin, B Yali, S Chi, SH Bak… - Oncotarget, 2016 - ncbi.nlm.nih.gov
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
[HTML][HTML] Comprehensive analysis of EGFR-mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations
X Li, W Cai, G Yang, C Su, S Ren, C Zhao, R Hu… - Journal of Thoracic …, 2017 - Elsevier
Introduction A qualitative detection method for EGFR mutations is not sufficient to guide
precise targeted therapy in clinical practice. The aim of this study was to explore the …
precise targeted therapy in clinical practice. The aim of this study was to explore the …
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
Q Zhou, JJ Yang, ZH Chen, XC Zhang, HH Yan… - Journal of Hematology & …, 2016 - Springer
Background Detecting epidermal growth factor receptor (EGFR) activating mutations in
plasma could guide EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment for advanced non …
plasma could guide EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment for advanced non …
Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients
N Matsuo, K Azuma, K Sakai, S Hattori, A Kawahara… - Scientific Reports, 2016 - nature.com
The most common event responsible for resistance to first-and second-generation (1st and
2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of …
2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of …
The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKI
Z Huang, Z Wang, H Bai, M Wu, T An, J Zhao… - Thoracic …, 2012 - Wiley Online Library
Background: The validity of epidermal growth factor receptor (EGFR) mutation in serum and
plasma DNA as a surrogate of tumor tissue has been comprehensively explored. However …
plasma DNA as a surrogate of tumor tissue has been comprehensively explored. However …
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
W Li, S Ren, J Li, A Li, L Fan, X Li, C Zhao, Y He, G Gao… - Lung cancer, 2014 - Elsevier
Background and purpose Continuous EGFR-TKI treatment beyond progression has shown
promising benefit for some patients with acquired resistance to EGFR-TKIs. The aim of this …
promising benefit for some patients with acquired resistance to EGFR-TKIs. The aim of this …
Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First …
JA Vendrell, J Mazieres, R Senal, I Rouquette… - Clinical Cancer …, 2019 - AACR
Purpose: The detection of preexisting EGFR T790M subclones and the assessment of their
clinical significance in the pretreatment of patients with EGFR T790M non–small cell lung …
clinical significance in the pretreatment of patients with EGFR T790M non–small cell lung …
Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
Z Wang, R Chen, S Wang, J Zhong, M Wu, J Zhao… - PloS one, 2014 - journals.plos.org
Background Among advanced non-small cell lung cancer (NSCLC) patients with an
acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
[HTML][HTML] Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors …
T Takahama, K Sakai, M Takeda, K Azuma, T Hida… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Methods We developed and evaluated liquid biopsy assays for detection of TKI-sensitizing
and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation–positive …
and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation–positive …
[HTML][HTML] EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing
L Lettig, N Sahnane, F Pepe, R Cerutti… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background Routine testing of baseline EGFR T790M mutation may have important clinical
impact but many discordant data have been reported regarding the diagnostic, prognostic …
impact but many discordant data have been reported regarding the diagnostic, prognostic …
相关搜索
- egfr mutations nsclc patients
- t790m mutation egfr tki
- longitudinal monitoring egfr tkis
- longitudinal monitoring nsclc patients
- lung cancer egfr tki
- response and resistance egfr tki
- dynamic monitoring egfr t790m
- treatment duration egfr tki
- digital pcr egfr tki
- acquired resistance egfr in plasma
- egfr mutations treatment decisions
- treatment decisions nsclc patients
- egfr mutations comprehensive analysis
- egfr mutations prospective screening
- prospective screening nsclc patients
- egfr mutations large scale